364 results
Keyword valsartan Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Amlodipine / Valsartan Mylan
Amlodipine besilate, valsartan, Hypertension
Date of authorisation: 22/03/2016,
, Revision: 10, Authorised, Last updated: 30/09/2022
Amlodipine / Valsartan Mylan Cardiovascular Diseases Vascular … Amlodipine / Valsartan Mylan … Amlodipine/Valsartan Mylan amlodipine / valsartan This is a summary of the … -
List item
Human medicine European public assessment report (EPAR): Dafiro
amlodipine, valsartan, Hypertension
Date of authorisation: 15/01/2007, Revision: 30, Authorised, Last updated: 11/11/2022amlodipine / valsartan … irbesartan, telmisartan, and valsartan) centrally. ARBs are available … olmesartan, telmisartan and valsartan 3 Sipahi I, Debanne SM … -
List item
Human medicine European public assessment report (EPAR): Entresto
sacubitril, valsartan, Heart Failure
Date of authorisation: 19/11/2015, Revision: 15, Authorised, Last updated: 02/09/2022sacubitril / valsartan … Entresto sacubitril / valsartan This is a summary of the … substances sacubitril and valsartan. It is used in adults with … -
List item
Human medicine European public assessment report (EPAR): Neparvis
sacubitril, valsartan, Heart Failure
Date of authorisation: 26/05/2016,
, Revision: 15, Authorised, Last updated: 02/09/2022
substances sacubitril and valsartan. It is used in adults with … 24 mg sacubitril / 26 mg valsartan, 49 mg sacubitril / 51 mg valsartan, and 97 mg sacubitril / 103 … 97 mg sacubitril / 103 mg valsartan). Neparvis can only be obtained … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Entresto, sacubitril, valsartan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000316-PIP02-11-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate solid oral dosage form
Decision date: 13/08/2021, Last updated: 31/08/2022, Compliance check: XActive substance sacubitril valsartan Therapeutic area Cardiovascular … investigation plan for sacubitril / valsartan (Entresto), (EMEA-000316-PIP02-11-M05 … investigation plan for sacubitril / valsartan (Entresto), (EMEA-000316-PIP02-11-M05 … -
List item
Summary of opinion: Entresto
sacubitril, valsartan, opinion date: 30/03/2023, Positive, Last updated: 31/03/2023sacubitril valsartan Opinion On 30 March 2023 … authorisation) Entresto sacubitril / valsartan On 30 March 2023, the Committee … resto Entresto sacubitril valsartan sacubitril valsartan … -
List item
Summary of opinion: Neparvis
sacubitril, valsartan, opinion date: 30/03/2023, Positive, Last updated: 31/03/2023sacubitril valsartan Opinion On 30 March 2023 … authorisation) Neparvis sacubitril / valsartan On 30 March 2023, the Committee … arvis Neparvis sacubitril valsartan sacubitril valsartan … -
List item
Human medicine European public assessment report (EPAR): Exforge HCT
valsartan, hydrochlorothiazide, Amlodipine besilate, Hypertension
Date of authorisation: 15/10/2009, Revision: 23, Authorised, Last updated: 21/12/2022amlodipine besilate / valsartan / hydrochlorothiazide … irbesartan, telmisartan, and valsartan) centrally. ARBs are available … olmesartan, telmisartan and valsartan 3 Sipahi I, Debanne SM … -
List item
Human medicine European public assessment report (EPAR): Copalia HCT
amlodipine, valsartan, hydrochlorothiazide, Hypertension
Date of authorisation: 03/11/2009, Revision: 23, Authorised, Last updated: 20/12/2022amlodipine / valsartan / hydrochlorothiazide … irbesartan, telmisartan, and valsartan) centrally. ARBs are available … olmesartan, telmisartan and valsartan 3 Sipahi I, Debanne SM … -
List item
Human medicine European public assessment report (EPAR): Dafiro HCT
valsartan, hydrochlorothiazide, Amlodipine besilate, Hypertension
Date of authorisation: 03/11/2009, Revision: 25, Authorised, Last updated: 20/12/2022amlodipine besilate / valsartan / hydrochlorothiazide … irbesartan, telmisartan, and valsartan) centrally. ARBs are available … olmesartan, telmisartan and valsartan 3 Sipahi I, Debanne SM … -
List item
Human medicine European public assessment report (EPAR): Exforge
valsartan, amlodipine (as amlodipine besilate), Hypertension
Date of authorisation: 16/01/2007, Revision: 31, Authorised, Last updated: 11/11/2022amlodipine / valsartan … irbesartan, telmisartan, and valsartan) centrally. ARBs are available … olmesartan, telmisartan and valsartan 3 Sipahi I, Debanne SM … -
List item
Human medicine European public assessment report (EPAR): Copalia
valsartan, amlodipine (as amlodipine besilate), Hypertension
Date of authorisation: 15/01/2007, Revision: 29, Authorised, Last updated: 11/11/2022amlodipine / valsartan … irbesartan, telmisartan, and valsartan) centrally. ARBs are available … olmesartan, telmisartan and valsartan 3 Sipahi I, Debanne SM … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Entresto, sacubitril, valsartan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000316-PIP03-20, Route(s) of administration: Oral use, Pharmaceutical form(s): Age-appropriate oral solid dosage form, Film-coated tablet, Granules
Decision date: 14/08/2020, Last updated: 18/06/2021, Compliance check: XActive substance sacubitril valsartan Therapeutic area Cardiovascular … specific waiver for sacubitril / valsartan (Entresto and associated … specific waiver for sacubitril / valsartan (Entresto and associated … -
List item
Human medicine European public assessment report (EPAR): Imprida
valsartan, amlodipine (as amlodipine besilate), Hypertension
Date of authorisation: 17/01/2007, Revision: 20, Withdrawn, Last updated: 11/05/2017controlled on amlodipine or valsartan monotherapy. More information … for Imprida (amlodipine / valsartan) in the European Union (EU … substances, amlodipine and valsartan. There are other medicinal … -
List item
Human medicine European public assessment report (EPAR): Imprida HCT
amlodipine, valsartan, hydrochlorothiazide, Hypertension
Date of authorisation: 15/10/2009, Revision: 3, Withdrawn, Last updated: 22/10/2012combination of amlodipine, valsartan and hydrochlorothiazide (HCT … irbesartan, telmisartan, and valsartan) centrally. ARBs are available … olmesartan, telmisartan and valsartan 3 Sipahi I, Debanne SM … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Exforge, valsartan, Amlodipine besilate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-001680-PIP01-14, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Orodispersible tablet
Decision date: 05/12/2014, Last updated: 17/02/2015, Compliance check: XExforge Active substance valsartan Amlodipine besilate Therapeutic … waiver Amlodipine (besylate) / valsartan for treatment of hypertension … Amlodipine (besylate) / valsartan for treatment of hypertension … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Imprida HCT, valsartan, hydrochlorothiazide, Amlodipine besilate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000399-PIP01-08, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 27/01/2009, Last updated: 06/03/2009, Compliance check: XKey facts Imprida HCT valsartan hydrochlorothiazide Amlodipine … for amlodipine besylate, valsartan, hydrochlorothiazide, (Imprida … for amlodipine besylate, valsartan, hydrochlorothiazide, (Imprida … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Copalia HCT, valsartan, hydrochlorothiazide, Amlodipine besilate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000397-PIP01-08, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 27/01/2009, Last updated: 06/03/2009, Compliance check: XCopalia HCT Active substance valsartan hydrochlorothiazide Amlodipine … for amlodipine besylate, valsartan, hydrochlorothiazide, (Copalia … for amlodipine besylate, valsartan, hydrochlorothiazide, (Copalia … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dafiro HCT, valsartan, hydrochlorothiazide, Amlodipine besilate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000398-PIP01-08, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 27/01/2009, Last updated: 06/03/2009, Compliance check: XDafiro HCT Active substance valsartan hydrochlorothiazide Amlodipine … for amlodipine besylate, valsartan, hydrochlorothiazide, (Dafiro … for amlodipine besylate, valsartan, hydrochlorothiazide, (Dafiro … -
List item
Referral: Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group
valsartan, candesartan, irbesartan, losartan, olmesartan, associated names: Karvezide, Karvea, Irbesartan/Hydrochlorothiazide Teva, Irbesartan Zentiva (previously Irbesartan Winthrop), Irbesartan Teva, Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), Ifirmasta (previously Irbesartan Krka), Ifirmacombi, Aprovel, Neparvis, Exforge, Exforge HCT, Entresto, Dafiro HCT, Dafiro, Copalia HCT, Copalia, Amlodipine / Valsartan Mylan , CoAprovel, Article 31 referrals
Status: European Commission final decision, opinion/position date: 12/11/2020, EC decision date: 19/02/2021, Last updated: 19/03/2021irbesartan, losartan, olmesartan, valsartan) Questions & Answers … irbesartan, losartan, olmesartan, valsartan) EMA/86733/2021 Page … irbesartan, losartan, olmesartan, valsartan) EMA/86733/2021 Page … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Copalia, varicella-zoster virus (live, attenuated)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Vaccines
PIP number: EMEA-001672-PIP01-14, Route(s) of administration: Subcutaneous use, Intramuscular use, Pharmaceutical form(s): Powder and solvent for suspension for injection
Decision date: 24/11/2014, Last updated: 12/12/2014, Compliance check: XCopalia Copalia amlodipine valsartan varicella-zoster virus (live … virus (live, attenuated) valsartan amlodipine (as amlodipine … -
List item
Referral: Diovan
valsartan, associated names: Angiosan, Diovane, Tareg, Cordinate, Provas, Dalzad, Rixil, Kalpress Cardio, Diovan Cardio, Miten Cardio, Valsartan Novartis, Article 29 paediatrics
Status: European Commission final decision, opinion/position date: 15/12/2009, EC decision date: 19/04/2010, Last updated: 31/05/2010Commission final decision Overview Valsartan (Diovan and associated names … dose of 320 mg since 2006. Valsartan has been approved and marketed … United States since 2007. Valsartan has also been approved for … -
List item
Referral: Diovan
valsartan, Article 30 referrals
Status: European Commission final decision, opinion/position date: 21/11/2008, EC decision date: 16/02/2009, Last updated: 13/03/2009inhibitors. But considering that valsartan given on its own is at least … hard capsules containing valsartan 40, 80, 160 or 320 mg The … inhibitors. But considering that valsartan given on its own is at least … -
List item
Referral: Diovan
valsartan, associated names: Angiosan, Diovane, Tareg, Cordinate, Provas, Dalzad, Rixil, Kalpress Cardio, Diovan Cardio, Miten Cardio, Valsartan Novartis, Kalpress, Miten, Article 29 paediatrics
Status: European Commission final decision, opinion/position date: 15/12/2009, EC decision date: 19/04/2010, Last updated: 31/05/2010Diovan Cardio Miten Cardio Valsartan Novartis Kalpress Miten About … International Non-proprietary Name: Valsartan Procedure No. EMEA/H/A-29 … children until recently. Valsartan (Diovan) is an angiotensin … -
List item
Referral: Diovan Comp
valsartan, hydrochlorothiazide, Article 30 referrals
Status: European Commission final decision, opinion/position date: 19/03/2009, EC decision date: 26/05/2009, Last updated: 11/06/2009contains two active substances, valsartan and hydrochlorothiazide Valsartan belongs to a class of medicines … blood pressure to increase. Valsartan works by blocking the effect … names tablets containing valsartan (80, 160 or 320 mg) and hydrochlorothiazide …